Efficacy of neo-adjuvant chemotherapy with TEC regimen on breast cancer.

about

Efficacy of neo-adjuvant chemotherapy with TEC regimen on breast cancer.

Item

http://www.wikidata.org/entity/Q41722410

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Efficacy of neo-adjuvant chemotherapy with TEC regimen on breast cancer.

@en

type

Item

label

Efficacy of neo-adjuvant chemotherapy with TEC regimen on breast cancer.

@en

prefLabel

Efficacy of neo-adjuvant chemotherapy with TEC regimen on breast cancer.

@en

P1476

Efficacy of neo-adjuvant chemotherapy with TEC regimen on breast cancer.

@en

P2093

Jiao Guo

http://www.w3.org/2001/XMLSchema#string

Long Chen

http://www.w3.org/2001/XMLSchema#string

Wen-Hai Zhang

http://www.w3.org/2001/XMLSchema#string

Xi Gu

http://www.w3.org/2001/XMLSchema#string

Yang Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer

Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer.

Emerging targeted therapies for breast cancer.

Genomic index of sensitivity to endocrine therapy for breast cancer.

Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies.

A Phase II Study of Concurrent Docetaxel, Epirubicin and Cyclophosphamide as a Neoadjuvant Chemotherapy Regimen in Patients with Locally Advanced Breast Cancer.

HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma.

A gene expression profile indicative of early stage HER2 targeted therapy response

Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.

P2888

s00280-014-2646-y

P304

301-308

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-014-2646-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1032318205

http://www.w3.org/2001/XMLSchema#string

P698

25480315

http://www.w3.org/2001/XMLSchema#string